(SEM) Select Medical Holdings - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US81619Q1058

Hospitals, Rehabilitation, Clinics

Stock: Health Care Facilities
Age 16.3y

MCap 1,887m
Avg Vol 625K (9.44M USD)

Beta 0.750
Volatility 34.81%

EPS (Earnings per Share)

EPS CAGR: -45.30%
EPS Trend: -17.7%

Last SUE: -1.70
Qual. Beats: 0

Revenue

Rev. CAGR: -3.52%
Rev. Trend: -26.6%

Last SUE: 0.06
Qual. Beats: 0

Dividends

Dividend Yield	1.73%
Yield on Cost 5y	1.78%
Yield CAGR 5y	-9.46%
Payout Consistency	47.2%
Payout Ratio	17.4%

Risk via 5d forecast
Volatility	34.8%
Value at Risk 5%th	51.0%
Relative Tail Risk	-10.97%

Reward TTM
Sharpe Ratio	-0.34
Alpha	-33.44
CAGR/Max DD	0.03

Character TTM
Hurst Exponent	0.569
Beta	0.750
Beta Downside	0.783

Drawdowns 3y
Max DD	45.06%
Mean DD	17.42%
Median DD	15.41%

Description: SEM Select Medical Holdings January 16, 2026

Select Medical Holdings Corp. (NYSE: SEM) runs a network of critical-illness recovery hospitals, rehabilitation hospitals, and outpatient rehab clinics across the United States, organized into three segments: Critical Illness Recovery, Rehabilitation Hospital, and Outpatient Rehabilitation. The first segment treats patients with heart failure, respiratory failure, renal disease, neurological events and trauma; the second focuses on therapy for brain/spinal injuries, strokes, orthopedic and cancer-related conditions; the third delivers physical, occupational and speech services plus specialty programs such as hand therapy, pelvic health and post-concussion care.

In FY 2023 the company generated roughly $1.64 billion in revenue with an adjusted operating margin of about 7 %, and its critical-illness hospitals reported an average occupancy rate near 85 %. Growth is being driven by macro-level trends: an aging U.S. population increasing demand for post-acute care, expanding Medicare Advantage enrollment that favors bundled-payment models, and a sector-wide shift toward outpatient rehabilitation that improves cost efficiency and patient throughput.

For a deeper, data-rich perspective on SEM’s valuation dynamics, you might find ValueRay’s analyst toolkit worth exploring.

Piotroski VR‑10 (Strict, 0-10) 2.0

Net Income (110.0m TTM) > 0 and > 6% of Revenue (6% = 236.0m TTM)

FCFTA 0.03 (>2.0%) and ΔFCFTA -1.34pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 2.06% (prev 2.62%; Δ -0.56pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.07 (>3.0%) and CFO 407.6m > Net Income 110.0m (YES >=105%, WARN >=100%)

Net Debt (971.5m) to EBITDA (232.7m) ratio: 4.17 <= 3.0 (WARN <= 3.5)

Current Ratio 1.09 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (123.5m) change vs 12m ago -0.97% (target <= -2.0% for YES)

Gross Margin 8.24% (prev 13.22%; Δ -4.99pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 57.47% (prev 75.60%; Δ -18.12pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 0.80 (EBITDA TTM 232.7m / Interest Expense TTM 103.7m) >= 6 (WARN >= 3)

Altman Z'' 0.88

(A) 0.01 = (Total Current Assets 1.02b - Total Current Liabilities 939.6m) / Total Assets 5.69b

(B) 0.15 = Retained Earnings (Balance) 824.8m / Total Assets 5.69b

(D) 0.22 = Book Value of Equity 818.7m / Total Liabilities 3.67b

Total Rating: 0.88 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 42.95

1. Piotroski 2.0pt

2. FCF Yield 6.09%

3. FCF Margin 4.42%

4. Debt/Equity 0.61

5. Debt/Ebitda 4.17

6. ROIC - WACC (= -4.55)%

7. RoE 6.51%

8. Rev. Trend -26.64%

9. EPS Trend -17.66%

What is the price of SEM shares?

As of January 17, 2026, the stock is trading at USD 15.36 with a total of 413,765 shares traded.
Over the past week, the price has changed by +0.92%, over one month by +0.59%, over three months by +15.51% and over the past year by -18.50%.

Is SEM a buy, sell or hold?

Select Medical Holdings has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy SEM.

Strong Buy: 4
Buy: 1
Hold: 1
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the SEM price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	18.4	19.8%
Analysts Target Price	18.4	19.8%
ValueRay Target Price	15	-2.6%

SEM Fundamental Data Overview January 13, 2026

P/E Trailing = 18.561
P/E Forward = 12.5156
P/S = 0.3515
P/B = 1.1156
P/EG = 1.37
Revenue TTM = 3.93b USD
EBIT TTM = 82.9m USD
EBITDA TTM = 232.7m USD
Long Term Debt = 1.74b USD (from longTermDebt, last quarter)
Short Term Debt = 213.0m USD (from shortTermDebt, last quarter)
Debt = 1.03b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 971.5m USD (from netDebt column, last quarter)
Enterprise Value = 2.86b USD (1.89b + Debt 1.03b - CCE 60.1m)
Interest Coverage Ratio = 0.80 (Ebit TTM 82.9m / Interest Expense TTM 103.7m)
EV/FCF = 16.43x (Enterprise Value 2.86b / FCF TTM 174.0m)
FCF Yield = 6.09% (FCF TTM 174.0m / Enterprise Value 2.86b)
FCF Margin = 4.42% (FCF TTM 174.0m / Revenue TTM 3.93b)
Net Margin = 2.80% (Net Income TTM 110.0m / Revenue TTM 3.93b)
Gross Margin = 8.24% ((Revenue TTM 3.93b - Cost of Revenue TTM 3.61b) / Revenue TTM)
Gross Margin QoQ = 10.81% (prev 11.60%)
Tobins Q-Ratio = 0.50 (Enterprise Value 2.86b / Total Assets 5.69b)
Interest Expense / Debt = 2.90% (Interest Expense 29.9m / Debt 1.03b)
Taxrate = 21.01% (11.7m / 55.9m)
NOPAT = 65.5m (EBIT 82.9m * (1 - 21.01%))
Current Ratio = 1.09 (Total Current Assets 1.02b / Total Current Liabilities 939.6m)
Debt / Equity = 0.61 (Debt 1.03b / totalStockholderEquity, last quarter 1.69b)
Debt / EBITDA = 4.17 (Net Debt 971.5m / EBITDA 232.7m)
Debt / FCF = 5.58 (Net Debt 971.5m / FCF TTM 174.0m)
Total Stockholder Equity = 1.69b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.61% (Net Income 110.0m / Total Assets 5.69b)
RoE = 6.51% (Net Income TTM 110.0m / Total Stockholder Equity 1.69b)
RoCE = 2.41% (EBIT 82.9m / Capital Employed (Equity 1.69b + L.T.Debt 1.74b))
RoIC = 1.88% (NOPAT 65.5m / Invested Capital 3.49b)
WACC = 6.42% (E(1.89b)/V(2.92b) * Re(8.68%) + D(1.03b)/V(2.92b) * Rd(2.90%) * (1-Tc(0.21)))
Discount Rate = 8.68% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.13%
[DCF Debug] Terminal Value 86.58% ; FCFF base≈245.4m ; Y1≈302.7m ; Y5≈515.6m
Fair Price DCF = 95.09 (EV 12.75b - Net Debt 971.5m = Equity 11.77b / Shares 123.8m; r=6.42% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -17.66 | EPS CAGR: -45.30% | SUE: -1.70 | # QB: 0
Revenue Correlation: -26.64 | Revenue CAGR: -3.52% | SUE: 0.06 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.44 | Chg30d=-0.002 | Revisions Net=-1 | Analysts=6
EPS next Year (2026-12-31): EPS=1.31 | Chg30d=-0.007 | Revisions Net=-1 | Growth EPS=+6.4% | Growth Revenue=+4.3%

Additional Sources for SEM Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle